Last reviewed · How we verify
remimazolam sedation reversal with flumazenil
Remimazolam, developed by the Medical University of Gdansk, is a marketed sedation agent that can be reversed with flumazenil, positioning it as a viable option in the sedation market. A key strength is its reversibility with flumazenil, which enhances patient safety and flexibility in clinical settings. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | remimazolam sedation reversal with flumazenil |
|---|---|
| Sponsor | Medical University of Gdansk |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: